ArticleJournal of conservative dentistry and endodontics2026
Cytocompatibility of calcium hydroxide medicament combined with cationic peptide - An
Article in Journal of conservative dentistry and endodontics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intracanal medication is recommended after the debridement of the canal to eliminate bacteria to prevent apical periodontitis. Combining calcium hydroxide (CH) with DJK-5 peptide will improve the penetration of medicament into root canal dentin. Aim: This study was performed to evaluate the cytotoxicity of a combination of DJK-5 peptide with CH on murine fibroblast cells. Settings and Design: This is an Materials and Methods: L929 fibroblast cells were grown in Dulbecco's Modified Eagle's Medium and administered with DJK-5 peptide at a concentration of 10 µg/mL, CH+ saline, CH+ 2% chlorhexidine (CHX), 2% CHX, and CH+ DJK-5 for 24 h and 48 h. Cytotoxicity assessment of the treatments was carried out using the methyl thiazolyl tetrazolium assay and Live/Dead assay by acridine orange and ethidium bromide dual-fluorescence staining. Statistical Analysis: One-way analysis of variance was used for group-wise comparison of cytotoxicity of the test compounds. Pairwise comparison between groups was analyzed by Tukey's test. Results: The DJK-5-treated group exhibited no cytotoxicity at 24 h and 48 h and exposure time points. Highest cytotoxicity was exerted by the 2% CHX-treated group, which increased when combined with CH, and the cytotoxicity increased with time. Combining the DJK-5 with CH reduced the cytotoxicity when compared to CH or CHX alone. Conclusions: At its used 2% concentration, CHX was found to exhibit high cytotoxicity. The least cytotoxicity was found in DJK-5-treated cells, and it also significantly alleviated the cytotoxicity rendered by CH treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.